The city of Salt Lake City, Utah, currently has 8 active clinical trials seeking participants for Healthy research studies.
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
Recruiting
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function. The study will also assess the safety and tolerability of the single dose of palovarotene. Participants will be enrolled in stages and divided into three groups based on their liver function: * Group 1: Healthy participants with... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/01/2025
Locations: J. Lewis Research Inc.-Foothill Family Clinic, Salt Lake City, Utah
Conditions: Hepatic Impairment, Healthy
Single and Multiple Ascending Dose Study and Food Effect Study for AG181
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AG-181 in healthy participants after oral administration of single ascending dose (SAD) of AG-181 in Part 1 and multiple ascending dose (MAD) in Part 2 along with the effect of food on the pharmacokinetics (PK) of single oral doses of AG-181 in healthy participants in Part 3.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/27/2025
Locations: ICON 1255 East 3900 South, Salt Lake City, Utah
Conditions: Healthy Volunteers
A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants
Recruiting
The main purpose of the study is to characterize the systemic pharmacokinetic (PK) parameters (plasma, whole blood) of tebipenem (TBP) pharmacologically active moiety of tebipenem-pivoxil-hydrobromide (TBP-PI-HBr) and its urinary excretion at different dose levels in healthy participants. The study also aims to assess the plasma and urine PK parameters of SPR1349, a major metabolite of TBP.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/25/2025
Locations: Medical Facility, Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Participants
A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants
Recruiting
The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/20/2025
Locations: ICON-Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Volunteers Sickle Cell Disease, Thalassemia
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
Recruiting
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/07/2025
Locations: ICON Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Volunteers
A First-In-Human Study of LY3985297 in Healthy Participants
Recruiting
The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it. The study is conducted in two parts (part A and B), each part has a separate treatment cohort. The stud... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/27/2025
Locations: ICON, Salt Lake City, Utah
Conditions: Healthy
Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets
Recruiting
This is a study to evaluate bioequivalence between adagrasib reference tablets and high drug load tablets in healthy adult participants.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/25/2025
Locations: ICON - Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Volunteers
A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception
Recruiting
This is a Phase I multicenter, open-label, dose-ranging, three-dose PK and PD study of injectable LB administered as an IM or SQ injection at 40 mg, and subsequently at 50mg SQ and then 60 mg SQ depending on the preliminary pharmacokinetic and pharmacodynamic results obtained with 40 mg dosing.
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
08/11/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Healthy Women, Female Contraception